Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 22553074)

1.

Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.

Dusetzina SB, Busch AB, Conti RM, Donohue JM, Alexander GC, Huskamp HA.

Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1251-60. doi: 10.1002/pds.3272. Epub 2012 May 3.

2.

Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.

Rubin DM, Kreider AR, Matone M, Huang YS, Feudtner C, Ross ME, Localio AR.

JAMA Pediatr. 2015 Apr;169(4):e150285. doi: 10.1001/jamapediatrics.2015.0285. Epub 2015 Apr 6.

PMID:
25844991
4.

Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.

Roberts AW, Dusetzina SB, Farley JF.

J Comp Eff Res. 2015 Jan;4(1):27-35. doi: 10.2217/cer.14.53.

PMID:
25565067
5.

Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior.

Miller CJ, Li M, Penfold RB, Lee AF, Smith EG, Osser DN, Bajor L, Bauer MS.

BMC Psychiatry. 2014 Nov 30;14:339. doi: 10.1186/s12888-014-0339-z.

6.

FDA-approved drugs to treat Schizophrenia.

[No authors listed]

J Psychosoc Nurs Ment Health Serv. 2013 Dec;51(12):9-10. doi: 10.3928/02793695-20131106-79. No abstract available.

PMID:
24305693
7.

Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs.

Hartung DM, Zerzan J, Yamashita T, Tong S, Morden NE, Libby AM.

Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):87-94. doi: 10.1002/pds.3538. Epub 2013 Oct 21.

PMID:
24142840
8.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

9.

Metabolic monitoring of patients prescribed second-generation antipsychotics.

Dhamane AD, Martin BC, Brixner DI, Hudson TJ, Said Q.

J Psychiatr Pract. 2013 Sep;19(5):360-74. doi: 10.1097/01.pra.0000435035.45308.03.

PMID:
24042242
10.

Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population.

Hartung DM, Middleton L, McFarland BH, Haxby DG, McDonagh MS, McConnell KJ.

Psychiatr Serv. 2013 Dec 1;64(12):1236-42. doi: 10.1176/appi.ps.005482012.

PMID:
23999754
11.

Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics.

Dusetzina SB, Mack CD, Stürmer T.

PLoS One. 2013 May 7;8(5):e63973. doi: 10.1371/journal.pone.0063973. Print 2013.

12.
13.

Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia.

Enger C, Jones ME, Kryzhanovskaya L, Doherty M, McAfee AT.

Int J Adolesc Med Health. 2013;25(1):3-11. doi: 10.1515/ijamh-2013-0002.

PMID:
23337048
14.

Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.

Dusetzina SB, Cook BL, Busch AB, Alexander GC, Huskamp HA.

Psychiatr Serv. 2013 Jan;64(1):83-7. doi: 10.1176/appi.ps.201200002.

15.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, Thiébaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. Epub 2012 Dec 13. French.

PMID:
23246328
16.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
17.
18.

Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey.

Kalsekar I, Wagner JS, DiBonaventura M, Bates J, Forbes R, Hebden T.

Health Qual Life Outcomes. 2012 Jul 17;10:81. doi: 10.1186/1477-7525-10-81.

19.

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims.

Stephenson JJ, Tunceli O, Gu T, Eisenberg D, Panish J, Crivera C, Dirani R.

Int J Clin Pract. 2012 Jun;66(6):565-73. doi: 10.1111/j.1742-1241.2012.02918.x. Epub 2012 May 11. Erratum in: Int J Clin Pract. 2012 Jul;66(7):723. Tuncelli, O [corrected to Tunceli, O].

20.

Studies may not provide clear view of antipsychotics.

Kuehn BM.

JAMA. 2012 Apr 18;307(15):1572. doi: 10.1001/jama.2012.499. No abstract available.

PMID:
22511673
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk